Abstract
Introduction: Despite policy interest in pharmaceutical innovation, little is known about the investment needed for venture capital–backed startups to develop innovative biologics, a growing segment of the pharmaceutical marketplace. Methods: In a cross-sectional analysis of Food and Drug Administration (FDA) drug approval data, investment deal records, and clinical trials data, we estimated the investment needed for a biotechnology startup company to independently develop a biologic approved by the US FDA with priority review, an indicator of innovation. To isolate a homogenous set of cases, the sample focused on independent drug development of 13 drugs by 9 biotechnology startup companies that retained ownership of the drug from the start of development to FDA approval without being acquired or licensing the product. Results: We found that the median investment per FDA-approved biologic was $304.1 million (IQR: $289.9–$790.3 million) in uncapitalized costs, accounting for the cost of failures. Conclusion: This estimate represents the direct drug R&D investment needed for independent development of innovative biologic products by biotechnology startup companies.
Funding Information
  • Agency for Healthcare Research and Quality (T32HS000029)